Market capitalization | €10.47b |
Enterprise Value | €22.58b |
PER (TTM) P/E ratio | 21.65 |
EV/FCF (TTM) EV/FCF | 11.66 |
EV/Sales (TTM) EV/Sales | 1.16 |
P/S ratio (TTM) P/S ratio | 0.54 |
P/B ratio (TTM) P/B ratio | 0.75 |
Dividend yield | 3.33% |
Last dividend (FY23) | €1.19 |
As a Free StocksGuide user, you can view scores for all 6,952 stocks worldwide.
23 Analysts have issued a Fresenius Medical Care forecast:
23 Analysts have issued a Fresenius Medical Care forecast:
Dec '23 |
+/-
%
|
||
Turnover | 19,454 19,454 |
0%
0%
|
|
Gross income | 4,933 4,933 |
7%
7%
|
|
EBITDA | 3,200 3,200 |
8%
8%
|
EBIT (operating result) EBIT | 1,587 1,587 |
9%
9%
|
Net profit | 499 499 |
26%
26%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
Head office | Germany |
CEO | Helen Giza |
Employees | 119,845 |
Founded | 1996 |
Website | www.freseniusmedicalcare.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.